Treintine HCl
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $12,982 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,982 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single-Dose Randomized Open-Label, Pilot Comparative Bioavailability Study of Trentine 250 mg Capsules (Amneal Pharmaceuticals) and SYPRINE (trientine hydrochloride) 250mg Capsules (Valeant Pharmaceuticals North America, USA) in Health Male and Female Volunteers under Fasting Conditions (2023) | Amneal Pharmaceuticals LLC | $12,982 | 0 |
Top Doctors Receiving Payments for Treintine HCl
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $12,982 | 1 |
Manufacturing Companies
- Amneal Pharmaceuticals LLC $12,982
Product Information
- Type Drug
- Total Payments $12,982
- Total Doctors 0
- Transactions 1
About Treintine HCl
Treintine HCl is a drug associated with $12,982 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Amneal Pharmaceuticals LLC.
Payment data is available from 2017 to 2017. In 2017, $12,982 was paid across 1 transactions to 0 doctors.
The most common payment nature for Treintine HCl is "Unspecified" ($12,982, 100.0% of total).
Treintine HCl is associated with 1 research study, including "A Single-Dose Randomized Open-Label, Pilot Comparative Bioavailability Study of Trentine 250 mg Capsules (Amneal Pharmaceuticals) and SYPRINE (trientine hydrochloride) 250mg Capsules (Valeant Pharmaceuticals North America, USA) in Health Male and Female Volunteers under Fasting Conditions (2023)" ($12,982).